Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca teams with Heptares

AstraZeneca has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders

AstraZeneca (AZ) has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders.

The deal includes a £3.8m payment to Heptares, which will also be eligible for royalties from any successful products, while AZ will gain the worldwide rights.

The collaboration will make use of Heptares' G protein-coupled receptors (GPCR) discovery expertise and proprietary technologies - including its StaR technology, which engineers stabilised receptors allowing GPCRs to be investigated.

GPCRs are one of the largest family of proteins, yet have an inherent instability when removed from cell membranes, according to a statement from AZ. 

Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders from projects in AZ's small and large molecule portfolio, including projects from AZ's biologics unit, MedImmune.

Martin Mackay, president of research and development, AZ, said: "Our work will focus on a range of different diseases across our small and large molecule portfolio with the goal of discovering innovative treatments for patients in areas of medical need."

31st May 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

Business in the USA
The pharma business environment in the US
Tighter regulations, more pricing controls and increased international competition will drive market improvements...
babylon virtual health service
VIDEO: Switching to a virtual health service
Ali Parsa, CEO and founder of babylon, discusses the benefits of conducting healthcare consultations via a smartphone...
Online Physician Communities
Is the pharma industry bad?
Surveys of doctors and the public suggest not...